
    
      This is an open label, multi-center, Phase 2 study of BBI608 administered in combination with
      either cetuximab, or panitumumab, or capecitabine. A cycle will consist of daily and
      continuous oral administration of BBI608 for four weeks in combination with either cetuximab,
      or panitumumab, or capecitabine.
    
  